Engineered immune cells take on viruses in cancer patients
NCT ID NCT05101213
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times
Summary
This early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and focuses on safety and feasibility, not yet on effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified virus-specific T-cells (CTLs)
- What this could lead to
- If successful, this could provide a new way to control dangerous viral infections in cancer patients who have weak immune systems, potentially reducing illness and death from these infections.
- What could go wrong
- This is a very early phase 1 trial with only 30 participants, so it is primarily testing safety and feasibility. The treatment may not work, and there could be side effects from the modified cells or the process of giving them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can a new PET tracer reveal hidden immune clues in tumors?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?
- Can specially grown immune cells from donors beat viruses that won't go away?
- A virtual pharmacy visit may ease opioid fears for cancer patients